Corporate Partners

NEWS

AMP v. Myriad - Decision Reached

AMP is very pleased with the Supreme Court’s decision in the case. The Court’s decision that human genes are not patentable is a great step forward for the field of molecular pathology, for genomic science, and most important for our patients. We look forward to exciting future advancements in diagnostic testing and therapeutics that will accrue to the benefit of our patients and our field.

View the Press Release

Link to decision from Supreme Court of the United States: http://www.supremecourt.gov/opinions/12pdf/12-398_8njq.pdf

REGISTRATION NOW OPEN for the AMP 2013 Annual Meeting

Join your colleagues, November 14-16, 2013 in Phoenix for the AMP Annual Meeting. Register early while prices are lower. Housing is open as well Note - by joining AMP or renewing your membership today, you'll receive the discounted member rate. More information...

AMP Joins FASEB!

June 2013: AMP has joined the Federation of American Societies for Experimental Biology (FASEB). "Being a member of FASEB will enable AMP's voice to be even stronger," said Jennifer L. Hunt, MD, MEd, AMP President.

View the Press Release

Professional Societies Delineate Concerns, Offer Recommendations Regarding Interim Pricing for Molecular Tests

May 2013: A coalition representing over 120,000 medical and laboratory professionals and institutions that perform the vast majority of clinical molecular pathology testing in the United States released a joint statement regarding new Medicare prices for those tests.
More Information...

Lung Biomarker Guideline Webcast Now Available

The guideline was developed to establish standards for testing for EGFR and ALK, helping to guide targeted therapies. Pathologists are encouraged to implement the new guideline at their institutions and into their practices to help improve the effectiveness of lung cancer treatment. More information...

View the webcast (wmv file)

Download the slides

AMP Identifies Flaws in AHRQ Report on Genetic Testing

April 2013: The AMP Professional Relations Committee commented on the AHRQ draft report, "Update on Genetic Tests Currently Available for Clinical Use in Common Cancers," identifying methodologic flaws in the data gathering process that have led to gaps in the report's findings.

View the Comments

View the AHRQ Draft Report

Health Information Technology Reform Act Reintroduced in the House

AMP reaffirms its initial comments stating the Act will address this misalignment between the regulations and pathology practice, and AMP wholeheartedly endorses this legislation.

View the Comments

Lung Biomarker Guideline Released by CAP, IASLC, & AMP

The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing in lung cancer, a uniform approach for testing for the EGFR mutation and ALK rearrangement along with the availability of targeted therapies offer lung cancer patients the chance for improved quality of life and more time with their loved ones. More Information...

Download the Guideline now.

AMPlifications - March 2013 Edition

View the most recent newsletter for updates on AMP members and leader's progress in advancing AMP via education, advocacy, and more. View the newsletter.

AMP Cautions FDA on Drug Labeling

March 2013: In a letter to the FDA, Jennifer L. Hunt, AMP President warned, "When the FDA includes a brand name of a diagnostic kit on a drug label, the medical community often views this as a tacit endorsement of that one company's test."

Read the letter.

Archived News

.....